| Bioactivity | BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves[1]. | ||||||||||||
| Target | IC50: 1.52 μM (hERG) | ||||||||||||
| Name | BKI-1369 | ||||||||||||
| CAS | 1951431-22-3 | ||||||||||||
| Formula | C23H27N7O | ||||||||||||
| Molar Mass | 417.51 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lee S, et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. Antimicrob Agents Chemother. 2018 Jun 26;62(7). |
BKI-1369
CAS: 1951431-22-3 F: C23H27N7O W: 417.51
BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activ
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.